← Back to Search

Anticoagulant

Apixaban for Myeloproliferative Neoplasm (AIRPORT-MPN Trial)

Phase 2
Waitlist Available
Led By Aurelien Delluc, MD, PhD
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up for the duration of the study follow-up period: 7 months
Awards & highlights

AIRPORT-MPN Trial Summary

This trial is studying a new drug, apixaban, to see if it is safe and effective in treating myeloproliferative neoplasms (MPNs), which are blood disorders that occur when the body makes too many white or red blood cells, or platelets.

Who is the study for?
This trial is for adults over 18 with specific blood disorders (PV, JAK2ET or pre-fibrotic MF) who can follow the study plan. It's not for those allergic to apixaban or aspirin, needing other blood thinners, with low platelets/Von Willebrand disease, kidney/liver issues, on conflicting meds, pregnant/breastfeeding women or without effective contraception.Check my eligibility
What is being tested?
The trial tests if a new oral blood thinner called Apixaban is better and safer than Aspirin in preventing blood clots in patients with certain myeloproliferative neoplasms (MPNs), which are conditions causing too many blood cells leading to clots.See study design
What are the potential side effects?
Apixaban may cause bleeding problems since it's a blood thinner. Other side effects could include bruising easily, nosebleeds, gastrointestinal bleeding and potentially serious bleeding events.

AIRPORT-MPN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~for the duration of the study follow-up period: 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and for the duration of the study follow-up period: 7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average monthly subject recruitment rate of all study sites during a 6-month recruitment period
Number of JAK2MPN patients recruited in 6 months in comparison to a target recruitment total of 39 prevalent cases and 5 incident cases at minimum
Quality of life on apixaban and aspirin will be measured through the use of the RAND 36-Item Health Survey (SF-36), with scores being transformed into a 0-100 scale where the higher the score the less disability.
+3 more
Secondary outcome measures
Percentage of incident and prevalent cases included in the study
Rate of all-cause mortality
Rate of combined arterial and venous thrombotic events (MI, stroke, transient ischemic attack, peripheral arterial thrombosis, VTE)
+4 more

AIRPORT-MPN Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Apixaban and cytoreductive therapy (if applicable)Experimental Treatment1 Intervention
Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.
Group II: Aspirin and cytoreductive therapy (if applicable)Active Control1 Intervention
Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,647 Total Patients Enrolled
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) NetworkNETWORK
10 Previous Clinical Trials
17,419 Total Patients Enrolled
the Association médicale universitaire de l'Hôpital Montfort (AMUHM)UNKNOWN

Media Library

Apixaban (Anticoagulant) Clinical Trial Eligibility Overview. Trial Name: NCT04243122 — Phase 2
Primary Myelofibrosis Research Study Groups: Apixaban and cytoreductive therapy (if applicable), Aspirin and cytoreductive therapy (if applicable)
Primary Myelofibrosis Clinical Trial 2023: Apixaban Highlights & Side Effects. Trial Name: NCT04243122 — Phase 2
Apixaban (Anticoagulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04243122 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Approximately how many individuals are engaged in this research?

"Affirmative. Clinical trials' website has published that this medical experiment, which was made public on February 17th 2021, is currently open for enrollment. A total of 46 individuals are desired from a single clinical facility."

Answered by AI

Has the FDA given authorization to Apixaban 2.5 MG Oral Tablet [ELIQUIS] yet?

"The safety of Apixaban 2.5 MG Oral Tablet [ELIQUIS] has been evaluated as a two on the scale from one to three, given that this is a Phase II trial with some evidence for its security but no data confirming efficacy."

Answered by AI

Is this an unprecedented clinical trial?

"Since its initial Phase 1 trial in 2005, sponsored by Abbott and involving 15480 patients, Apixaban 2.5 MG Oral Tablet [ELIQUIS] has been studied extensively with 207 active studies in 1452 cities across 62 countries leading to its approval for use as a medication."

Answered by AI

What purposes does Apixaban 2.5 MG Oral Tablet [ELIQUIS] usually serve?

"Apixaban 2.5 MG Oral Tablet [ELIQUIS] is typically prescribed for deep vein thrombosis, but it may also be effective in mitigating death by myocardial infarction, back pain and after procedures such as percutaneous coronary intervention (PCI)."

Answered by AI

Is access to this experiment available for prospective participants?

"According to the information posted on clinicaltrials.gov, recruitment for this medical study is still ongoing. The trial was initially created February 17th 2021 and recently modified April 19th 2022."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
The Ottawa Hospital
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
2021. "Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04243122.
All > Appendix Cancer > Durlaza
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top